Compare URGN & AIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | URGN | AIV |
|---|---|---|
| Founded | 2004 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | 1994 |
| Metric | URGN | AIV |
|---|---|---|
| Price | $21.96 | $5.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $28.50 | $10.00 |
| AVG Volume (30 Days) | 998.4K | ★ 1.5M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | ★ 48.88% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.72 |
| Revenue | $96,516,000.00 | ★ $210,889,000.00 |
| Revenue This Year | $27.96 | $6.96 |
| Revenue Next Year | $123.02 | N/A |
| P/E Ratio | ★ N/A | $3.72 |
| Revenue Growth | 8.00 | ★ 39.67 |
| 52 Week Low | $3.42 | $5.24 |
| 52 Week High | $30.00 | $9.29 |
| Indicator | URGN | AIV |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 55.11 |
| Support Level | $21.74 | $5.58 |
| Resistance Level | $30.00 | $5.62 |
| Average True Range (ATR) | 1.56 | 0.07 |
| MACD | -0.72 | 0.05 |
| Stochastic Oscillator | 3.15 | 98.00 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment; Operating, and Other. Development and Redevelopment segment consists of properties that are under construction or have not achieved stabilization, as well as land held for development. Operating segment includes 20 residential apartment communities with 5,243 apartment homes that have achieved a stabilized level of operations. Other segment includes The Benson Hotel, company's only hotel. Majority of revenue is gained from Operating Segment.